Navigation Links
Phase 3 Results Show Canagliflozin as Add-On Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients with Type 2 Diabetes
Date:11/9/2012

research, and these results further support the efficacy and safety profile of canagliflozin," said Kirk Ways, M.D., Ph.D., Vice President and Compound Development Team Leader for canagliflozin at Janssen. "The data are in line with the Phase 3 results announced earlier this year at the annual meetings of the American Diabetes Association and European Association for the Study of Diabetes which suggest that canagliflozin could help control blood glucose in a wide range of patients with type 2 diabetes, including patients on other antihyperglycemic medications such as pioglitazone and metformin."

These results are included in the abstract, "Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes on Metformin and Pioglitazone" (board #64). An additional abstract, "Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes with Moderate Renal Impairment" (board #75) will also be presented at CODHy 2012.

About Canagliflozin

Canagliflozin is an investigational sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of patients with type 2 diabetes. The kidneys of people with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to non-diabetic people, which may contribute to elevated glucose levels. Canagliflozin blocks the reabsorption of glucose by the kidney, increasing glucose excretion and lowering blood glucose levels.

The global Phase 3 canagliflozin clinical program, which enrolled 10,285 patients in nine studies, is the largest late-stage development program for an investigational pharmacologic product for the treatment of type 2 diabetes submitted to health authorities to date. The program evaluated the safety and efficacy of canagliflozin across the spectrum of type 2 diabetes management, from adult patients treated only with diet and exercise to those requiring insulin injections to maintain glycemic control, and in three large studies in special populations: older p
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... First Choice Wellness Care recently upgraded their ... is the only clinic in the greater ... The practice has recently expanded their services and added ... their focus in the procedure. They upgraded to the ... clearance, and superior service. "We,ve been providing ...
(Date:6/30/2015)... , June 30, 2015 Today, UBM China, ... an agreement with Chengdu Tianyi Exhibition Co., Ltd. to ... which is to be held concurrently with CWMEE 2016. ... UBM,s healthcare exhibition family, following MEDTEC China and DENTECH ... market in west China. It,s also another concrete cooperative ...
(Date:6/30/2015)... , June 30, 2015 Oramed ... a clinical-stage pharmaceutical Company focused on the development of ... patient has been screened in the Company,s Phase IIb ... based study will be performed under the active Investigational ... Food and Drug Administration (FDA). The Phase ...
Breaking Medicine Technology:First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3UBM Joins Chengdu Tianyi to Hold CWMEE 2016 2UBM Joins Chengdu Tianyi to Hold CWMEE 2016 3Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 2Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 3
... WOODLANDS, Texas, Oct. 27, 2011 Lexicon Pharmaceuticals, ... company focused on discovering breakthrough treatments for human disease, ... 2011 financial results on Tuesday, November 1, 2011 before ... conference call to discuss program status and financial results ...
... Oct. 27, 2011 Cardica, Inc. (Nasdaq: CRDC ... ended September 30, 2011. Cardica,s management will host a conference ... financial results and provide an update on the company,s business. ... team of Dr. Swanstrom, a world-renowned key opinion leader in ...
Cached Medicine Technology:Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results 2Cardica Announces Fiscal 2012 First Quarter Financial Results 2Cardica Announces Fiscal 2012 First Quarter Financial Results 3Cardica Announces Fiscal 2012 First Quarter Financial Results 4Cardica Announces Fiscal 2012 First Quarter Financial Results 5Cardica Announces Fiscal 2012 First Quarter Financial Results 6
(Date:6/30/2015)... ... , ... According to a June 15th report from USC News, ... stimuli can be used to “decrease children’s anxiety and negative responses during oral care.” ... compare patient experience in a “typical dental environment” with one that provides “visual, auditory ...
(Date:6/30/2015)... ... June 30, 2015 , ... After many requests ... finally its here, http://www.express-glasses.com is proud to announce its collaboration with ... about shipping with DHL Express when calling or visiting the express glasses website. ...
(Date:6/30/2015)... ... ... Rocky Mountain Oils, a leading non-MLM supplier of premium essential oils, today ... Darold Francis. The changes will help enhance the company’s focus on strict product quality ... know and respect for over eight years. , “I am thrilled to join the ...
(Date:6/30/2015)... ... June 30, 2015 , ... MJH Associates ... HRA Healthcare Research & Analytics , a consultative healthcare market research practice ... family of businesses. HRA offers quantitative and qualitative, custom and multi-client primary market ...
(Date:6/30/2015)... ... June 30, 2015 , ... An opinion ... that fat transfer procedures had over breast implants when reconstructing breasts after a ... that “look and feel natural,” have increased sensation, and are less likely than ...
Breaking Medicine News(10 mins):Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3
... Antares, parent company, Medical Mutual of Ohio to ... processes, reduced costs, improved ... Software, developer of the,OnBase document and process management ... Management Solutions as the new provider of,enterprise document ...
... LISTERINE(R) Products Launch New Children,s Fluoride Rinse, with Special Tinting ... ... MORRIS PLAINS, N.J., March 11 Parents confess that kids,can ... care.,According to a recent survey of parents with children ages six ...
... of EUSA,s Transatlantic ... Commercialization Platform ... EUSA Raises Over US$50 Million to Fund Acquisition and Other ... Pharma Inc (,EUSA,), a transatlantic specialty pharmaceutical company,focused on oncology, ...
... LifeMasters Supported,SelfCare, Inc., a national leading ... announced it has received $15 million in ... one of its,earliest investors, Saints Capital, and ... financial flexibility to continue to execute on,its ...
... Will Address Attorney Weight Loss Coaching and Present Ideas On How ... ... Leventhal Weight Loss,Incorporated, the first in the nation executive weight ... that its president and founder Mark Leventhal, Esq. will address,the Washington, ...
... Made to Deny Union for Healthcare Employees in Ohio, ... (CNA) has launched an anti-union campaign against nurses,and other ... by the workers to unite in District 1199 of ... votes -- this Wednesday and Friday at nine Catholic,Healthcare ...
Cached Medicine News:Health News:Antares Management Solutions Selects Hyland Software's OnBase 2Health News:The Disappearing Toothbrush: Survey Reveals Kids' Top Excuses to Avoid Brushing 2Health News:The Disappearing Toothbrush: Survey Reveals Kids' Top Excuses to Avoid Brushing 3Health News:The Disappearing Toothbrush: Survey Reveals Kids' Top Excuses to Avoid Brushing 4Health News:EUSA Pharma to Acquire US Specialty Oncology Company Cytogen 2Health News:EUSA Pharma to Acquire US Specialty Oncology Company Cytogen 3Health News:EUSA Pharma to Acquire US Specialty Oncology Company Cytogen 4Health News:EUSA Pharma to Acquire US Specialty Oncology Company Cytogen 5Health News:LifeMasters Strengthens Capital Structure with $15 Million in Funding from Existing Investors 2Health News:LifeMasters Strengthens Capital Structure with $15 Million in Funding from Existing Investors 3Health News:Mark Leventhal To Address Nixon Peabody LLP 2Health News:SEIU: 'Union-Busting' by California Nurses Association 2
Six inch wide elastic belt transfers the apron weight off the shoulders. 0.5mm front and 0.25mm back with a generous overlap for double protection. Shoulder pads included. Also available without wide...
Front protection with choice of adjustable 2" buckle or velcro belt which crosses the back for a comfortable fit. Adjustable straps at shoulders keeps apron snug....
... Versatile, pocket-size peripheral ... either a full-function nerve ... block monitor, depending upon ... is attached. Includes NSL-5 ...
Low pressure automatic tourniquet with manual time. Includes extension hose and spiral replacement hose....
Medicine Products: